SCHEMBL8167630

SCHEMBL8167630

O=C(O)Cc1c(C(=O)c2cccc(-c3cccc(Cl)c3Cl)c2)oc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ NPSR1 Q6W5P4 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ PTPN1 P18031 2/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ MCL1 Q07820 2/20 0.40
▸ CTSA P10619 1/20 0.40
▸ BCL2L1 Q07817 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ RXRA P19793 1/20 0.39
▸ RXRB P28702 1/20 0.39
▸ RXRG P48443 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8175782 0.87 ALDH1A1 (0.47) MAPTALDH1A1NPSR1SMN1; SMN2KDM4E
SCHEMBL8179582 0.85 MAPT (0.44) MAPTALDH1A1NPSR1SMN1; SMN2KDM4E
SCHEMBL8167631 0.84 RXRA (0.48) MAPTALDH1A1NPSR1SMN1; SMN2KDM4E
SCHEMBL8178074 0.79 MTNR1A (0.43) PTPN1CTSARXRARXRBRXRG
SCHEMBL8180878 0.78 RXRA (0.43) MAPTALDH1A1NPSR1SMN1; SMN2KDM4E
SCHEMBL8165108 0.77 KDM4E (0.43) MAPTALDH1A1KDM4EHPGDMCL1
SCHEMBL8167484 0.77 PTPN1 (0.56) MAPTALDH1A1NPSR1SMN1; SMN2KDM4E
SCHEMBL4254952 0.75 MAPT (0.40) MAPTALDH1A1NPSR1SMN1; SMN2KDM4E
SCHEMBL8166735 0.70 KDM4E (0.44) MAPTALDH1A1KDM4EMCL1
SCHEMBL5841701 0.70 RXRA (0.57) MCL1BCL2L1RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 — — US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 — — US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS MAPT 3958/4885ALDH1A1 1836/4885NPSR1 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback